ASXL1 mutation is believed to be an early mutational event that confers a competitive growth advantage to HSCs in various myeloid malignancies [72], even in the early stages of idiopathic cytopenia of undermined significance [75], a condition characterized by unexplained low blood cell counts without a definitive diagnosis of hematologic malignancy. Here, ASXL1 is linked to myeloid neoplasm.